FDA Staff Reviewers Report Higher Number Of Deaths In Donanemab-Treated Participants Compared To Placebo; Deaths Not Fully Explained By ARIA Or Cerebral Hemorrhage
Portfolio Pulse from Benzinga Newsdesk
FDA staff reviewers have reported a higher number of deaths in participants treated with Donanemab compared to those given a placebo. The deaths were not fully explained by ARIA or cerebral hemorrhage.
June 06, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FDA staff reviewers have reported a higher number of deaths in participants treated with Eli Lilly's Donanemab compared to those given a placebo. The deaths were not fully explained by ARIA or cerebral hemorrhage.
The report from FDA staff reviewers indicating a higher number of deaths in Donanemab-treated participants is likely to negatively impact Eli Lilly's stock price in the short term. The lack of a clear explanation for the deaths adds to the uncertainty and potential risk associated with the drug.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100